

# Resource Summary Report

Generated by [Kravitz](#) on Sep 10, 2026

## University of Colorado Anschutz Medical Campus Cancer Center Pathology Shared Resource Molecular Pathology Core Facility

RRID:SCR\_021995

Type: Tool

---

### Proper Citation

University of Colorado Anschutz Medical Campus Cancer Center Pathology Shared Resource Molecular Pathology Core Facility (RRID:SCR\_021995)

---

### Resource Information

**URL:** <https://medschool.cuanschutz.edu/colorado-cancer-center/research/shared-resources/pathology/molecular-pathology>

**Proper Citation:** University of Colorado Anschutz Medical Campus Cancer Center Pathology Shared Resource Molecular Pathology Core Facility (RRID:SCR\_021995)

**Description:** Molecular Pathology Section offers clinical grade sample processing and molecular testing for research cases. All services are performed in CLIA certified environment and all molecular assays are accompanied by full data analysis including bioinformatics analysis for NGS data.

**Abbreviations:** PSR-MP

**Synonyms:** Pathology Shared Resource - Molecular Pathology, Molecular Pathology

**Resource Type:** access service resource, core facility, service resource

**Keywords:** ABRF, USEDit, clinical grade sample processing, molecular testing, CLIA certified environment

**Resource Name:** University of Colorado Anschutz Medical Campus Cancer Center Pathology Shared Resource Molecular Pathology Core Facility

**Resource ID:** SCR\_021995

**Alternate IDs:** ABRF\_1318

**Alternate URLs:** <https://coremarketplace.org/?FacilityID=1318>

**Record Creation Time:** 20220421T050138+0000

**Record Last Update:** 20260905T133423+0000

---

## Ratings and Alerts

No rating or validation information has been found for University of Colorado Anschutz Medical Campus Cancer Center Pathology Shared Resource Molecular Pathology Core Facility.

No alerts have been found for University of Colorado Anschutz Medical Campus Cancer Center Pathology Shared Resource Molecular Pathology Core Facility.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 4 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [Kravitz](#) .

Eule CJ, et al. (2025) Clinical features and mutational frequency of renal cell carcinoma from patients undergoing kidney transplant evaluation. *Frontiers in oncology*, 15, 1526545.

Maleddu A, et al. (2025) Novel PLEC-EML4-ALK Double Fusion Underlying Crizotinib Resistance in a Metastatic Inflammatory Myofibroblastic Tumor: A Case Report. *JTO clinical and research reports*, 6(5), 100791.

French JD, et al. (2024) Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(17), 3757.

Priest K, et al. (2023) Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway. *NPJ precision oncology*, 7(1), 9.